4
Changes in Ownership
Denali Therapeutics Inc. Filed Acc 0001209191-23-002179
President and CEO sold 5,029 shares at $28.73 ($144,483)
- President and CEO acquired 82,240 shares (grant or award)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Watts Ryan J. President and CEO | 2023-01-03 | Grant or award | +82,240 | 231,934 | D: show line 1 in the form | ||
| Watts Ryan J. President and CEO | 2023-01-04 | Sale | −5,029 | $28.73 | $144,483 | 2,213,464 | I: show line 2 in the form |
| Open-market sales · 5,029 sh · avg $28.73 · $144,483 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Watts Ryan J. President and CEO | 2023-01-03 | Grant or award · Stock Option (right to buy) | +246,720 | 246,720 | D: show line 3 in the form |
Loading xslF345X03/doc4.xml…